ArticleVaccine2016
A trivalent vaccine candidate against hepatitis E virus, norovirus, and astrovirus.
Article in Vaccine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Umbrella review of the safety of Chikungunya vaccine platforms used in other vaccines.Human vaccines & immunotherapeutics · 2025Pooled it
- Updated Estimates of the Global, Regional and National Burden, and Etiology of Diarrheal Diseases Transmissible via Food: A Systematic Review and Meta-Analytical Modelling Study for the World Health Organization.medRxiv : the preprint server for health sciences · 2026Article
- Article
- A bioengineered pseudovirus nanoparticle displaying SARS-CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS-CoV 2 challenge.Biotechnology journal · 2023Article
- Review
- The αTSR Domain ofInternational journal of nanomedicine · 2023Article
- Bioengineered pseudovirus nanoparticles displaying the HA1 antigens of influenza viruses for enhanced immunogenicity.Nano research · 2022Article
- Review
- Epidemiology and evolution of Norovirus in China.Human vaccines & immunotherapeutics · 2021Review
- Structural Insights into the Human Astrovirus Capsid.Viruses · 2021Review
- Vaccines against gastroenteritis, current progress and challenges.Gut microbes · 2020Review
- Molecular characterization of canine astrovirus, vesivirus and circovirus, isolated from diarrheic dogs in Turkey.Iranian journal of veterinary research · 2020Article
- Norovirus Capsid Protein-Derived Nanoparticles and Polymers as Versatile Platforms for Antigen Presentation and Vaccine Development.Pharmaceutics · 2019Review
- Immune response and protective efficacy of the S particle presented rotavirus VP8* vaccine in mice.Vaccine · 2019Article
- Evidence for an unknown agent antigenically related to the hepatitis E virus in dairy cows in the United States.Journal of medical virology · 2019Article
- Bioengineered Norovirus SACS nano · 2018Article
- Saliva as a source of reagent to study human susceptibility to avian influenza H7N9 virus infection.Emerging microbes & infections · 2018Article
- Progress on norovirus vaccine research: public health considerations and future directions.Expert review of vaccines · 2018Review
- Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future.Current drug metabolism · 2018Review
- Outbreak of caliciviruses in the Singapore military, 2015.BMC infectious diseases · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
Hepatitis E virus (HEV), norovirus (NoV), and astrovirus (AstV) are enterically-transmitted viral pathogens causing epidemic or endemic hepatitis (HEV) and gastroenteritis (NoV and AstV) respectively in humans, leading to significant morbidity and mortality worldwide. While a recombinant subunit vaccine against HEVs is available in China, there is no commercial vaccine or antiviral against NoV or AstV. We report here our development of a trivalent vaccine against the three viral pathogens through our new polymer vaccine technology. All HEV, NoV, and AstV are non-enveloped RNA viruses covered by a protein capsid, featuring surface protruding (P) proteins that are responsible for virus-host interaction. These dimeric P proteins elicit neutralizing antibody and are good targets for subunit vaccine development. The trivalent subunit vaccine was developed by fusion of the dimeric P domains of the three viruses together that formed tetramers. This trivalent vaccine elicited significantly higher antibody responses in mice against all three P domains than those induced by a mixture of the three free P domains (mixed vaccine). Furthermore, the post-immune antisera of the trivalent vaccine showed significantly higher neutralizing titers against HEV infection in cell culture and higher blocking activity against NoV binding to HBGA ligands than those of the post-immune sera of the mixed vaccine. Thus, the trivalent vaccine is a promising vaccine candidate against HEV, NoV, and AstV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.